A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
Phase of Trial: Phase III
Latest Information Update: 15 Jan 2020
Price : $35 *
At a glance
- Drugs Mepolizumab (Primary) ; Salbutamol
- Indications Acute asthma; Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jan 2020 Planned End Date changed from 1 Mar 2021 to 30 Nov 2022.
- 10 Jan 2020 Planned primary completion date changed from 1 Mar 2021 to 30 Nov 2022.
- 23 Sep 2019 Planned End Date changed from 1 Feb 2021 to 1 Mar 2021.